Announcements Trials
Browse Landscape

Phase

Phase 2 63Phase 1/2 24Phase 1 23Phase 3 9Phase NA 5Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 2

Status

Recruiting 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Propofol 9Sevoflurane 7Rituximab 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Trastuzumab 5Enoxaparin 5Bevacizumab 5Nivolumab 4Carboplatin 4Capecitabine 4Bupivacaine 4trametinib 3pirtobrutinib 3pembrolizumab 3dabrafenib 3atezolizumab 3apixaban 3Lenalidomide 3Indocyanine Green 3Gemcitabine 3Docetaxel 3Cyclophosphamide 3zanubrutinib 2venetoclax 2trastuzumab deruxtecan 2ribociclib 2polyethylene glycol 3350 2pertuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Recruiting × Azacitidine × Clear all
NCT07044687 2026-05-12

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

AbbVie

Phase 4 Recruiting
100 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06370000 2026-03-02

REMAIN1

Virginia Commonwealth University

Phase 4 Recruiting
12 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡